Announced
Completed
Financials
Sources
Tags
Domestic
Majority
Merger
United States
Completed
Single Bidder
clinical-stage neuroscience
Pharmaceuticals
Private
Acquisition
Friendly
Synopsis
Adamis Pharmaceuticals, a biopharmaceutical company developing therapeutics for respiratory diseases and cancer, completed the acqusition of DMK Pharmaceuticals, a privately held, clinical-stage neuroscience company. Financial terms were not disclosed. “Last fall, we initiated a process to explore strategic alternatives for the company with the goal of maximizing stockholder value. After engaging in a thorough process of exploring potential alternatives and transactions, we believe a merger with DMK is the best path forward for Adamis and the strategy that has the potential to deliver significant value to Adamis’ shareholders. I believe by combining Adamis’ commercial products and development infrastructure with DMK’s clinical-stage programs and library of small molecules, under Dr. Versi’s leadership, the new company will have the potential to develop multiple groundbreaking treatments and ultimately grow shareholder value,” David J. Marguglio, Adamis CEO.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.